+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin



Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin



Molecular Diagnosis and Therapy 21(1): 95-105



Statins are the mainstay hypercholesterolemia treatment and reduce the risk of cardiovascular events in patients. However, statin therapy is often interrupted in patients experiencing musculoskeletal pain or myopathy, which are common in this patient group. Currently, the standard tests for diagnosing statin myopathies are difficult to interpret. A pharmacogenomics (PGx) test to diagnose statin-induced myopathy would be highly desirable. We developed a Markov state model to assess the cost-effectiveness of a hypothetical PGx test, which aims to identify statin-induced myopathy in high-risk, secondary prevention cardiovascular patients. The alternative strategy hypothesized is that physicians or patients interrupt the statin therapy in the presence of musculoskeletal pain. Our model includes health states specific to the PGx test outcome which assesses the impact of test errors. Assuming a perfect test, the results indicate that the PGx test strategy dominates when the test costs less than CAN$356, when the strategy is cost neutral. These results are robust to deterministic and probabilistic sensitivity analyses. Our base-case results show that a PGx test for statin-induced myopathy in a high-risk, secondary prevention of a cardiovascular event population would be a dominant solution for a test cost of CAN$356 or less. Furthermore, the modelling of the complete range of diagnostic test outcomes provide a broader understanding of the economic value of the pharmacogenomics test.

(PDF emailed within 0-6 h: $19.90)

Accession: 057685365

Download citation: RISBibTeXText

PMID: 27798813

DOI: 10.1007/s40291-016-0238-8


Related references

Economic Evaluation Of A Pharmacogenomic Test For Statin-Induced Myopathy In Cardiovascular High-Risk Patients Initiating A Statin. Value in Health 18(7): A396, 2015

A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Molecular Diagnosis and Therapy 22(2): 241-254, 2018

Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy. Circulation Journal 82(4): 1008-1016, 2017

Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. Molecular Diagnosis and Therapy 2018, 2018

Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. Pharmacoeconomics 2019, 2019

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. American Journal of Cardiology 89(4): 390-394, February 15, 2002

Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. Plos One 3(6): E2522, 2008

Large copy-number variations in patients with statin-associated myopathy affecting statin myopathy-related loci. Physiological Research 65(6): 1005-1011, 2016

Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. Journal of Pharmacy Practice 30(5): 521-527, 2016

Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmunity Reviews 12(12): 1177-1181, 2014

LDL cholesterol response and statin adherence among high-risk patients initiating treatment. American Journal of Managed Care 22(3): E106-E115, 2017

Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors. Indian Journal of Pharmacology 47(5): 563-564, 2016

Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medicine 163(5): 553-564, 2003

Mislabeling of Study Design and Overstatement of Findings in "Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment". Journal of Pharmacy Practice 30(3): 385, 2018

Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients. Musculoskeletal Care 8(1): 2-9, 2010